The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
VYVGART (Argenx Australia Pty Ltd)
Product name
VYVGART
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
119 (255 working days)
Active ingredients
efgartigimod alfa
Registration type
NCE/ NBE
Indication
Vyvgart is indicated as an add-on to standard therapy for the treatment of adult patients with generalised Myasthenia Gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive.